Aseptika Releases SENSOR I App: The Clinical Version of Activ8rlives on Apple’s App Store

HUNTINGDON, U.K. - April 19, 2015 - PRLog -- Aseptika makes available the SENSOR I App for iPads to support clinical studies in respiratory research and for those with long-term respiratory conditions who want to self-monitor and self-manage their health at home.

The SENSOR suite of Apps was designed and trialled in collaboration an NHS Trust in a clinical trial funded by NHS England, which has just been successfully completed in Hampshire, through the highly acclaimed Small Business Research Initiative (SBRI) Healthcare programme.

The App was designed for use by people of any age, but is especially inclusive for older patients. The colourful user interface, the step-by-step instructions and motivational messages enable the user to collect 40 vital signs and questions about their daily health, all in less than 10 minutes a day.

The volunteer patients daily measured, without supervision: lung function by simple spirometry, blood oxygen saturation, blood pressure, heart rate, levels of physical activity and body composition, alongside a number of questions capturing the data routinely requested in paper-based questionnaires, which are generally only undertaken at the start, middle and end of research studies.

The response of volunteers (average age 67) on the clinical trial has been highly positive.

The SENSOR I App collects and displays the data on that day for the key vital signs and displays these to the user but the user is “blinded” to the longitudinal data – useful in clinical research studies. These data are simultaneously uploaded to Activ8rlives’ UK-based web-servers for review as a cohort by clinical teams through a dedicated clinician portal in Activ8rlives. The ownership of the data is retained by the user at all times, but can be shared (by permission of the user) with the ecosystem of care workers, supporters and family who are involved in their care.

The SENSOR II App will be released shortly in which users in future randomised controlled trials are unblinded to their longitudinal data, which is displayed as charts and bar charts as they record their vital signs on a daily basis to enable them to self-monitor and self-manage their respiratory disease at home and to watch for signs of impending ill health associated with respiratory exacerbations.

Kevin Auton Ph.D, Managing Director of Aseptika commented:

“The release of the SENSOR I App via the Apple Store is an important milestone for Aseptika. It supports the increasing use of self-monitoring at home by the patient as policy makers shift the balance of care from hospitals to the home and the community throughout the EU. The SENSOR App suite are tools which can be used to facilitate a new partnership between the patient and their clinical teams and complement the new Activ8rlives v3.0 App, which shares many of the same features as SENSOR but is designed for use by the consumer.”

SENSOR I and the Activ8rlives 3.0 Apps are free to download. There is no charge to the patient for the use of Activ8rlives to securely and confidentially store their data. The decision to share data with clinical teams remains at the sole discretion of the user.

- Ends –

Caption: The newly launched medical SENSOR I App for respiratory research and self-management of respiratory disease available from the Apple Store for iPads (iPad 3 or above, iPad Mini 2 or above, iPad Air 2 or above running iOS 8.2 or above) and also available on NHS Choices App Store soon.

About Aseptika Limited (Activ8rlives):

Aseptika Limited is a healthcare company developing and marketing an integrated suite of self-monitoring devices and services under the Activ8rlives brand. We are developing integrated systems which can be used by laypeople and their healthcare service providers to better self-manage (http://www.activ8rlives.com/solutions/self-monitoring-and...) long-term health conditions (LTHC) through self-monitoring.

The Company’s goal is to provide everyone with tools (and the understanding of how to apply them) so that most of us can keep healthy and well for most of the time. Self-management through self-monitoring is the motivation driving what we do.

Activ8rlives is unusual in that we are device agnostic, incorporating sensors and monitors ranging from consumer accessories to in vitro diagnostics (IVDs) with a focus on respiratory disease. All data is held together and can be cross analysed in the Cloud to provide forecasts and learning for the user and clinician.

The Company gained the UK patent in 2013 protecting the invention of a test for biomarkers (http://www.activ8rlives.com/about/news-and-events/news/20...) of Pseudomonas aeruginosa (PA) in the sputum of patients, which can be used to detect the on-set of an exacerbation and profile the efficacy of antibiotic treatment for each patient.

Aseptika won first place in a competition earlier in 2014 to reward the most “Promising eHealth EU SME”eHealth solution 2014 (http://www.activ8rlives.com/about/news-and-events/news/2014/04/03/aseptika-wins-first-place-for-most-promising-ehealth-solution-competition-2014/#sthash.jm6jQb3Q.dpuf)developed by an early-stage European SME. The 2014 Competition was organized by TICBioMed and had the endorsement of the Health and Wellbeing Unit of DG CONNECT of the European Commission. The judges commended Aseptika for the integrated approach it was taking in the support of patients with long-term respiratory disease (http://www.activ8rlives.com/solutions/clinical-trials/), providing the platform to self-manage their illness through self-monitoring. Central to the Company’s “hospital-at-home” concept, is a test in which the patient measures the level of virulence of the bacteria living in their lungs which from time to time, flare into a full and repeated chest infections.

Aseptika was a shortlisted finalist for the Cambridge News Top Innovations 2014 (http://www.cambridge-news.co.uk/Innovations-2014/story-22802672-detail/story.html) and AXA PPP Health Tech & You (http://tr.axa-ppp.co.uk/do?B1D6C55B52E4CA5F29BAC297AFEC96616BEED2ADFC11507352CB0B093683219668A1A1FDC5BE1F9AAFCFBA515D62693465C0057B22D451DBCA5F71EBBA9990A9) Awards. Winner of the Discovery Start-up 2014 Competition (http://www.cambridgewireless.co.uk/news/article/default.aspx?objid=47697) run by Cambridge Wireless and Winner of the Hunts Post Huntingdonshire Business Innovation Awards 2014 (http://www.huntsbusinessawards.co.uk/). Named on Global Digital Health 100 Award (http://www.thejournalofmhealth.com/#!The-Journal-of-mHealth-Announces-the-2014-Global-Digital-Health-100-Recognising-the-Most-Innovative-Digital-Companies-in-Healthcare/cuhk/8C07B55F-084F-4C3E-BD3D-4A63343372FA) list, reflecting the importance of mobile and digital solutions.

Wearable Technology Awards 2015 (http://www.wearabletechnologyshow.net/awards) Aseptika was shortlisted in three categories: Best Innovation, Overall Wearable Winner and was placed third in the Best Medical Device category.

Aseptika was granted a patent in the United States (US) protecting its invention for a test for respiratory infections in March 2015.

For more information on Aseptika Ltd, Activ8rlives and products, please visit: www.Activ8rlives.com

Activ8rlives, Activ8rlives.com, BuddyWOTCH and EyKos are trademarks of Aseptika Ltd.

For press information, please contact:

Jessica Auton, Marketing Director

jessica.auton@aseptika.com

Direct +44 (0)1480 352 821

Mobile +44 (0)7455 922 122